Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) expanded its collaboration with PathAI to deploy AISight Dx, an FDA-cleared digital pathology platform, across Labcorp's national anatomic pathology labs and hospital collaborations on Feb. 23, 2026. The cloud-based system enables fully digital workflows, AI-powered image analysis, secure storage and connectivity.
According to the company, deployment aims to scale digital slide review, improve turnaround times, enhance collaboration and support Labcorp's precision medicine products, building on a 2019 strategic investment in PathAI and prior AI-driven clinical trial support.
Labcorp (NYSE: LH) reported Q4 2025 revenue of $3.52B and full-year revenue of $13.95B (up 7.2% year-over-year). Full-year adjusted EPS rose to $16.44 (from $14.57), and free cash flow was $1.21B. The company provided 2026 guidance: enterprise revenue $14.61B–$14.79B, adjusted EPS $17.55–$18.25, and free cash flow $1.24B–$1.36B.
Operational highlights include 13 strategic transactions, >130 new tests launched, the first FDA-cleared blood test for Alzheimer’s in primary care, and a planned 500,000 sq ft Central Laboratory investment.
Labcorp (NYSE: LH) announced nationwide availability of the Elecsys® pTau-181 blood test cleared by the FDA to aid initial assessment of Alzheimer’s disease in primary care for symptomatic patients aged 55 and older. The test offers a 97.9% negative predictive value, is performed by simple blood draw at Labcorp's >2,200 patient service centers, and aims to reduce reliance on brain scans or lumbar punctures. Developed by Roche Diagnostics and FDA-cleared in 2025, the test complements Labcorp's biomarker portfolio and supports diagnostic and therapeutic workflows, including contributions to >90 Alzheimer's protocols across 45 countries.
Labcorp (NYSE: LH) appointed John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors effective February 9, 2026.
Dr. Sampson is vice chancellor for health affairs and dean at University of Colorado Anschutz School of Medicine, a practicing neurosurgeon, National Academy of Medicine member, and will join the Quality and Compliance Committee.
Labcorp (NYSE: LH) announced a quarterly cash dividend of $0.72 per share. The dividend is payable on March 12, 2026 to shareholders of record at the close of business on February 27, 2026.
Labcorp (NYSE: LH) expanded its Labcorp Plasma Detect molecular residual disease (MRD) portfolio on Jan 13, 2026, adding Plasma Detect ID for stage I–III breast cancer and stage I–IIIA non-small cell lung cancer and nationwide availability of Plasma Detect Genome for stage III colon cancer.
Both tests report a limit of detection (LOD95) of 0.005% for circulating tumor DNA (ctDNA). The company cited recurrence rates ranging from 10%–55% for NSCLC, 10%–40% for breast cancer, and about 35% for stage III colon cancer, and noted peer-reviewed studies and AMP 2025 data supporting clinical utility.
Visby Medical (LH) expanded consumer access to its FDA-authorized at-home Women’s Sexual Health Test, a palm-sized PCR device delivering lab-quality results in ~30 minutes for chlamydia, gonorrhea, and trichomoniasis. As of November 2025 the test is purchasable on questhealth.com, and it is now available on Labcorp OnDemand; Ovia Health by Labcorp plans employer/health-plan distribution in early 2026. The test enables a self-collected vaginal swab, secure app results, and links to same-day virtual care and medication via third-party providers, aiming to reduce testing delays and untreated STI complications.
NAMSA (ARCHIMED portfolio) completed the acquisition of the U.S. assets of Labcorp's Early Development medical device testing business on Jan 8, 2026, expanding NAMSA's U.S. service portfolio to include biocompatibility, microbiological, analytical testing and preclinical research.
The deal positions NAMSA as a broader end-to-end MedTech testing partner, transfers Labcorp Early Development device projects to NAMSA facilities in Ohio, Minnesota, Georgia and California, and is NAMSA's 10th acquisition since joining ARCHIMED in 2020.
Labcorp (NYSE: LH) will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, 2026 at 4:30 p.m. PT. A live audio webcast will be available on the company investor relations site ir.Labcorp.com and will be archived for replay.
The presentation offers investors and analysts direct access to management commentary on strategy and market outlook; no financial results or guidance are included in this announcement.
Labcorp (NYSE: LH) completed the acquisition of select ambulatory outreach laboratory assets from Community Health Systems subsidiary CHS for approximately $194 million in cash on December 2, 2025.
The sale covers outreach lab services, certain patient service centers and in‑office phlebotomy locations in 13 states. CHS will continue to operate inpatient and emergency department laboratories and hospital-based lab services. Labcorp said the transaction expands access to its specialty testing menu, data analytics and digital tools for CHS‑affiliated patients and providers.